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Identification of a compound series by High Throughput Screening capable of reversing 
the antiviral effect of Ribavirin in tissue culture 
 
Introduction 
Many RNA viruses represent a severe health risk through chronic infections and sporadic 
epidemics  [1]. Their  rapid  mutation  rate  complicates  the  treatment  and  prevention  of 
diseases such as Human Immunodeficiency Virus (HIV), Hepatitis C, and Influenza [2-
4]. Viral populations exist as a collection of genetically related mutants undergoing rapid 
adaptive evolution [5]. An infected individual can harbor multiple genotypically unique 
but related mutants of the same species, each capable of continued adaptive changes, 
making the treatment and management of an infection difficult [6]. The mutation rate of a 
viral population is dictated by the fidelity, or error rate, of the polymerase enzyme used. 
The RNA-dependent RNA polymerase of riboviruses operates with a characteristically 
low  fidelity  for  the  RNA  strand  and  has  an  error  rate  of  10
-3  to  10
-5  mutations  per 
nucleotide per replication event. This represents several orders of magnitude greater than 
the  replication  error  rate  of  organisms  with  a  DNA  genome  and  results  in  rapidly 
evolving  viral  populations  [7,8,9].  Given  the  large  population  size  of  a  typical  viral 
infection, it is possible that a population is at any time composed of mutants expressing 
every point mutation possible as well as many double mutations [7].  
Quasispecies theory, originally used to describe population dynamics in the “precellular 
RNA  world”,  has  been  experimentally  validated  to  further  describe  the  population 
dynamics of RNA viruses [7,10,11,12]. The rapid rate of evolution coupled to a near 2 
 
infinite population size creates a cloud of genetically distinct mutants, each contributing 
to the characteristics of the viral phenotype [14]. To varying extents for specific viruses, 
the standing genetic diversity of the genome population is curtailed by a selective loss of 
variants  due  to  competitive  disadvantages  relative  to  the  wild  type.  These  specific 
variants  would  be  lost  from  the  population  further  strengthening  the  population  as  a 
whole.  
Alterations  in  the  overall  structure  and  composition  of  the  variants  composing  the 
population can drastically alter the pathogenesis of the virus [15,16,17]. While previous 
work on RNA viruses has focused on the replicative fitness of viral clones, fitness in a 
viral  quasispecies  is  primarily  dependent  on  the  mutation  and  adaptation  rate  of  the 
population as a whole rather than an individual mutant's replicative ability [1]. There is 
however an upper limit to the number of mutations per replication, known as the error 
threshold  [1].  A  polymerase  that  operates  past  this  threshold  causes  a  buildup  of 
deleterious mutations in the resulting progeny, inducing an “error catastrophe” and lethal 
mutagenesis of the population [1]. RNA viruses have evolved with an optimized mutation 
rate thereby maximizing the diversity of the resulting viral population without crossing 
this threshold [18,19]. By operating just under the error threshold the population as a 
whole  can  exist  in  many  different  environments,  which  would  have  otherwise  been 
outside the range of the original “master” virion.  
Recent research has focused on using lethal mutagenesis as a natural form of antiviral 
defense and can be used as a viable therapeutic option in some viral infections [20,21]. 
Compounds which decrease the fidelity of the RDRP would push viral populations past 3 
 
the error threshold resulting in the buildup of deleterious mutations. Of the compounds 
being tested, nucleoside analogs have shown the most promise. Ribavirin is a nucleoside 
analog  with  broad  anti-viral  activity,  and  is  currently  used  therapeutically  against 
respiratory syncytial virus (RSV) and HCV as well as demonstrating lethal mutagenesis 
in Hantaan and Polio viruses [22,23,24].  
An alternate therapeutic option is paradoxically presented by increasing the fidelity of the 
RDRP. By limiting the mutation rate of viral quasispecies   the maintained genotypic 
homogeneity results in a less fit, more treatable infection [1]. In dynamic environments a 
high  mutation  rate  represents  an  evolutionary  advantage  and  is  advantageous  to  viral 
growth. While each variant may be less fit than the original genotype, the population has 
the ability to quickly adapt to an environmental pressure, such as an immune response. A 
viral population lacking this flexibility to adapt would not be able to mutate in response 
to a selective pressure and would therefore be more vulnerable to antiviral treatments. 
This theory has been effectively shown by two groups working on the polio virus [25,26]. 
A mutant with an altered polymerase resulting in a higher fidelity replication was less 
virulent and less capable of infection when compared to the wild type [27]. 
Using High Through-put Screening of a compound library, SIGA Technologies developed 
a  screen  to  identify  compounds  capable  of  increasing  the  fidelity  of  an  RNA  virus’s 
RDRP. Using Influenza H1N1 as a model virus, the screen uses ribavirin to artificially 
push Influenza past the error threshold resulting in an error catastrophe and inhibition of 
viral  growth.  Co-treatment  with  compounds  that  increase  polymerase  fidelity  would 
inhibit the mutagenic effect of RBV saving the population from the error catastrophe and 4 
 
resulting in a normal viral infection. A “hit” is any compound which reverses the anti-
viral effects of RBV.  
Due  to  the  nature  of  this  screen,  positive  hits  may  be  compounds  that  simply  act 
antagonistically to RBV thereby negating its mutagenic effects in a manner independent 
from the RDRP. Current research is unclear on RBV's mechanism of action in Influenza, 
although there are many proposed possibilities [28,29,30,31]. Firstly, RBV may act on the 
viral polymerase either as a viral mutagen decreasing polymerase fidelity [32,33,34] or 
by termination of chain elongation through incorporation of RBV triphosphate by the 
RDRP [35,36,37]. Alternatively ribavirin may inhibit activity of inosine monophosphate 
dehydrogenase  (IMPDH)  the  host  enzyme  that  catalyzes  de  novo  synthesis  of  GTP 
[38,39,40]. Inhibition of IMPDH would result in a reduction of purine nucleotide pools 
necessary  for  viral  replication.  Due  to  the  uncertainty  in  RBV’s  MOA,  a  compound 
showing promise in reversing the action of RBV may be acting in one of many ways to 
inhibit RBV, requiring the necessity of subsequent testing.  
A compound which increases RDRP polymerase fidelity would limit a virus’s ability to 
quickly  mutate  around  the  selective  pressures  of  antiviral  treatments  and  immune 
responses. Limiting the mutation rate of a quasispecies population would severely inhibit 
their ability to rapidly gain resistance to current antiviral treatments and leave them more 
vulnerable to therapeutic options.  If used concurrently with antivirals a compound that 
increases RDRP fidelity might not only control acquired resistance but also limit the 
development of emergent infections possibly leading to eradication. 
 5 
 
Methods 
Cell Lines and Materials 
Except  where  specified  all  experiments  were  conducted  using  Madin-Darby  Canine 
Kidney  (MDCK)  cells.  These  cells  were  maintained  in  Eagle’s  Modified  Essential 
Medium (EMEM) purchased from ATCC (catalog # 30-2003) supplemented with 10% 
fetal  bovine  serum  (Invitrogen  Catalog  #10082-147),  and  100  U  of  penicillin-
streptomycin  (penstrep)/ml  (Invitrogen  Catalog  #15140-163).  Cells  beyond  passage 
number  25  were  not  used  experimentally.  MDCK  cells  were  seeded  in  serum  free 
MDCK-ULTRA media supplemented with 100 U penstrep for each experiment. Fetal 
bovine  serum  was  excluded  as  it  interferes  with  glycosidic  hydrolase  activity  of  the 
influenza viral protein neuraminidase which is necessary for cellular entry. All cells were 
maintained at 37°C with 5% CO2. 
Zanamivir  (Catalog  #M-1826)  was  purchased  from  Moravek.  The  chemical  2’-(4-
Methylumbelliferyl)-α-D-N-acetylneuraminic  acid  (4-MUNANA)  was  purchased  from 
Sigma Aldrich (Catalog #M8639). MDCK-ULTRA culture media (Catalog #BW12749Q) 
and Cell Titer-Glo Luminescent Cell Viability Assay Kit (Catalog # PR-G7571) were 
purchased from Fisher Scientific. 
 
Influenza Virus Infection 
Influenza A (H1N1) stocks were grown from a single purified plaque and concentrated to 
2x10
6 PFU/ ml in 500 ul aliquots and stored at -80° C. Individual aliquots were thawed as 
needed. All assays used an MOI of 0.05 to 0.08. Viral infection media was supplemented 6 
 
with  1.0  ug/ml  TPCK  Trypsin  prior  to  infection  to  aid  in  influenza  cellular  entry. 
Influenza  viral  growth  assays  were  incubated  at  37°C  with  5%  CO2  for  72  hours. 
Determination of viral growth was based on the quantification of neuraminidase activity 
by measuring fluorescence of the cleaved substrate 4-MUNANA. 
 
Primary High Throughput Screening  
Ninety-six well plates were initially seeded with 5000 MDCK cells/well in 150 ul MDCK 
ULTRA media supplemented 1% antibiotic (100 U Penicillin/Streptomycin/ml). 
After allowing 24 hours for cell adherence, each well was treated with 10 uM of a unique 
compound from SIGA's compound library. Plates were then infected with Influenza virus 
at 250 PFU/well for an MOI of 0.05. With the exception of the virus only (positive) and 
no virus (negative) control wells, 45 uM RBV (EC90) was also added to each well to 
inhibit viral growth. Virus was allowed to incubate for 72 hours post infection at 37°C 
with 5% CO2. 
Readout for this screen measures the neuraminidase activity (NA) in each well using     
10 uM of the synthetic substrate 2’-(4-Methylumbelliferyl)-α-D-N-acetylneuraminic acid 
(4-MUNANA).  Neuraminidase,  a  glycoside  hydrolase,  cleaves  4-MUNANA  into  4-
methylumbelliferone (4-MU) which can be measured fluorometrically. The amount of 
fluorescence  per  well  is  a  direct  representation  of  the  NA  activity,  which  is  further 
correlated to the amount of virus present in the well. Comparison of this value to the 
virus only controls allows calculation of the percent viral growth per well. 
After  a  one  hour  incubation  at  37°C,  NA  hydrolase  activity  was  quenched  with  the 7 
 
addition  of  150  ul  stop  solution  (25%  Ethanol  and  75%  0.1M  glycine  pH  10.7). 
Fluorescence was excited at 350 nm and emission was measured at 465 nm using an 
Envision Plate Reader. 
 
Secondary Screening  
Hits from primaries were run in triplicate 7-point dilutions to measure the dose dependent 
response  of  the  compound  against  an  EC50  concentration  of  RBV  and  to  measure 
cytotoxicity as a result of treatment (CC50). Cytotoxicity was measured in the absence of 
viral  infection  using Alamar  Blue  as  an  indicator  of  cellular  metabolic  health. These 
plates were read fluorometrically with an excitation of 570 nm and an emission of 600 
nm and compared to cell only control wells to allow calculation of percent viability in 
each  well.  Viral  growth  in  the  EC  plates  was  determined  from  NA  activity  on  4-
MUNANA. 
 
Tertiary Screen assay development 
Cell density 
Tertiary screening was moved into a 384 well format using MDCK cells in serum free 
MDCK-ULTRA media. The optimal seeding density was found using a 1:2 cell dilution 
series with 8 replicates per dilution. These were then incubated at 37°C for 120 hours. 
Determination of cell growth in the presence and absence of compound or virus was 
based on the amount of ATP/well measured with 25 uL/well Cell Titer Glo [13]. 
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Influenza Virus Infection 
A  TCID90  was  conducted  using  a  half-log  20  point  dilution  series  beginning  at  a 
multiplicity of infection (MOI) of 2.4. Eight replicates were used at each MOI. The 4-
MUNANA/NA  readout  was  used  as  described  previously  in  order  to  quantify  viral 
growth. 
Mutagen Antiviral Activity 
Using the optimal cell density and viral concentration, multiple mutagens were tested in 
20 point dilutions from 250 uM down to 1 uM with four replicates per concentration. 
Mutagens were dispensed using an HP D300 Digital Dispenser. Readouts used the 4-
MUNANA/NA assay described above. Viral inhibition curves were then created using the 
relative  neuraminidase  activity  per  mutagen  concentration  compared  to  virus  only 
controls. Cytotoxicity of each mutagen was quantified using Alamar Blue. 
 
Antagonism Screening 
The activity of compounds from secondaries was measured against multiple mutagens 
discovered from Tertiary  screening in a 384-well plate format. Plates were seeded as 
previously described above with 5000 cells/well in 45 uL MDCK-ULTRA and after 24 
hours were treated with a 7 point range of RBV dilution down columns 2-11 and 12-22 
and then co-treated with a 10 point dilution of RIC compound across this dilution in rows 
B-H and I-O. This resulted in four 8x11 quadrants with each well representing a different 
combination of RBV and RIC-compound, and each row representing a dilution of RIC 
compound  against  a  constant  concentration  of  RBV.  From  this  data  an  EC50 9 
 
concentration  of  RIC-compound  was  found  against  seven  different  concentrations  of 
RBV. The extra column (22) represented a RBV only control dilution in the absence of 
RIC and the extra rows (H and O) were a RIC compound control in the absence of RBV.  
“Virus only” and “no-virus” control wells were placed in columns 23 and 24. 
EC plates were infected with influenza at an MOI of 0.05 and cytotoxicity plates were 
mock infected with 5 ul ULTRA supplemented with TPCK. Total assay volume was 50 
uL/well. 
Plates were incubated for 72 hours at 37°C. Viral growth in the EC plates was measured 
with 4-MUNANA and cell growth in the cytotoxicity plates was measured using Titer-
GLO, 25 uL/well as specified by Promega. 
 
Emergent Mutation Assay 
Four white 384 well plates were initially seeded with MDCK cells at a density of 5000 
cells/well in 45 ul of serum free MDCK-ULTRA media. After 24 hours each plate was 
treated with a different experimental condition. All wells of plate A were treated with    
12 nM (EC50) Zanamivir (Zan); Plate B was treated with 1.92 uM RIC-2; Plate C was 
treated with both 12 nM Zanamivir and 1.92 uM RIC-2; and Plate D was treated with an 
equivalent  concentration  of  DMSO  to  act  as  a  virus  only  control.  All  plates  were 
normalized to the same DMSO concentration of 1.12 uM. All wells were then infected 
with 150 PFU Influenza (MOI of 0.03). Virus was incubated for 72 hours at 37°C. 
After 72 hours of viral growth samples from passage 1 wells were passed into fresh 
culture plates by diluting 2 ul from each well in the passage 1 plates into 198 ul MDCK 10 
 
ULTRA. Two microliters of this dilution was then transferred to the corresponding well 
of the passage 2 plates. The passage 2 plates had been seeded 24 hours previous in a 
manner consistent with passage 1 plates and were treated as described above with the 
specified  compound  for  each  treatment  group.  In  this  way,  virus  from  well A1  from 
passage 1 was diluted and transferred to well A1 of the passage 2 plate. The virus was 
thus serially passaged 4 times for a total viral growth period of 17 days in the presence of 
each  treatment  type. After  each  transfer  of  virus  to  the  new  passage  plates,  the  viral 
growth in the preceding passage was fluorometrically measured using 4-Munana. 
 
Pre-incubation for chemical interaction between RIC-1 series and Ribavirin 
In order to rule out a direct chemical interaction between the RIC series and Ribavirin, 
the  two  compounds  were  added  to  “neat”  media  in  a  dilution  plate  and  allowed  to 
incubate  for 6, 3 and 0 hours at 37°C. Each addition time point had 3 replicates of a 6 
point range of RIC-1 concentrations (18.0 uM, 10.8 uM, 4.5 uM, 1.8 uM, 0.9 uM, and 
0.18 uM) against 810 uM RBV. Additional treatment groups were, three replicates of 810 
uM RBV incubated for six hours with 10.8 uM RIC-1 added at T=0, and three replicates 
of 10.8 uM RIC-1 incubated for 6 and 3 hours with 810 uM RBV added at T=0. In 
addition, there were three replicate wells of ribavirin only and RIC-1 only controls at 
each time point. 
A 96 channel liquidator was used to transfer 10 ul from the 96 well dilution plate to two 
separate 96 well tissue culture plates which had been seeded with 5000 MDCK cells/well 
in 150 ul MDCK-ULTRA 24 hours prior. Plates were then infected at an MOI of 0.05 in a 11 
 
final volume of 170 ul. Since the dilution plate was concentrated the 1 to17 dilution from 
the dilution plate to the 384 well assay plate resulted in the desired RIC concentrations of 
1.0 uM, 0.6 uM, 0.25 uM, 0.1 uM, 0.05 uM, and 0.01 uM and a RBV concentration of 45 
uM RBV (EC90).  
Infected cells were incubated as previously described for 72 hours and viral growth was 
measured using 4-MUNANA. All replicates were averaged and compared to virus only 
control wells for percent viral growth. Cell viability was measured using 100uL/well of 
Titer-Glo as specified by Promega. 
 
Pre-incubation of RIC-1 and RIC-2 to measure rate of association 
MDCK cells were seeded at 5000 cells/well in 150 uL ULTRA media in 96 well plates. 
After 24 hours of incubation, cells were treated at different time intervals with three 
replicates of a 5 point dilution of RIC-1 ranging from 1.5 uM to 0.05 uM. A separate plate 
was  treated  in  the  same  way  with  RIC-2  ranging  from  3.0  uM  down  to  0.1  uM. 
Compounds were added at time points T= -4.5 hours, -60 minutes, -30, -15, -5, and -2.5 
minutes.  All plates were then rinsed thoroughly four times with 200 uL cold DPBS to 
remove any trace of non-bound RIC. Individual washes consisted of multiple “pipetting 
up and down” steps in order to physically rinse the monolayer. Cells were again covered 
in 150 uL MDCK-ULTRA. 
The same 5 point dilutions of RIC-1 and RIC-2 were added in duplicate to the remaining 
untreated wells. To act as a control all wells were then treated with 45 uM RBV, with the 
exception of virus only and cell only controls. 12 
 
Plates  were  infected  with  influenza  as  specified  in  primaries  and  viral  growth  was 
measured  after  72  hours  using  4-MUNANA.  Duplicate  plates  were  carried  without 
infection and cell viability was measured using Alamar Blue. 
 
Ribavirin Uptake 
Six well plates were seeded with 1.2x10
6 MDCK cells per well in 2 ml MDCK-ULTRA 
and incubated at 37°C for 24 hours. Using one plate per sample group, six treatments 
were used; 150 uM RBV, 750 uM RBV, 1500 uM RBV, 150 uM RBV with a long wash, 
150 uM RBV + 5 uM RIC-1, and 150 uM RBV + 50 uM NBMPR. Plates were first 
incubated with RIC-1, NBMPR, or a media control for 1 hour to attain complete activity. 
Ribavirin was then added to all plates and incubated for 20 minutes to allow equilibration 
into the cell. The media from all wells was removed and the monolayers were washed 
with  1  ml  4°C  DPBS  for  4  seconds  to  remove  extracellular  RBV.  The  “long  wash” 
samples received two separate 30 second washes with 4°C DPBS. Half the wells were 
then lysed with 600 uL acetonitrile for 2 minutes followed by disruption of the mono 
layer with a cell scraper. This volume was then aspirated from each well and transferred 
to a second well of the same treatment group in order to collect cells from two wells into 
the same 600 uL volume. Each six well plate therefore resulted in three unique replicates 
each consisting of cells collected from two wells. The RBV concentration in each sample 
was measured using mass spectroscopy against an internal standard. 
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Interaction of RIC series with the inhibition of the IMPDH pathway 
Using  the  “four  quadrant  384  well”  format  previously  described  in  the  “antagonism 
screening” a dilution of RIC-1 was tested against multiple concentrations of the IMPDH 
inhibitor  Mycophenolic  Acid  (MPA).  Influenza  growth  in  each  well  was  based  on 
neuraminidase activity in comparison to the virus only  controls. Duplicate uninfected 
plates were carried as a measure of cytotoxicity using Cell Titer Glo. Compounds were 
dispensed using an HP D300 Digital Dispense instrument. 
 14 
 
Results 
 
High-Throughput Screening 
Primary  screening  of  SIGA's  compound  library  against  a  viral  infection  artificially 
inhibited by the addition of 45 uM Ribavirin revealed a compound series that reversed the 
antiviral effect of RBV resulting in the return of viral growth to control levels. This series 
consisted  of  hundreds  of  individual  compounds  each  composed  of  a  conserved  core 
structure consisting of “purine nucleoside-like” fused ring structure. Differences between 
each compound within the series were limited to substitutions, additions, or subtractions 
of side groups attached to the central structure. These modifications resulted in an altered 
degree of activity against RBV. Further testing in secondary screening verified the initial 
hits  with  an  eight  point  dilution,  providing  an  approximate  EC50  value  for  each 
compound (data not shown). The lead compounds from this series were then tested in a 
20 point dilution against variable levels of RBV for an established EC50 value at each 
RBV  concentration.  Figure  1  shows  inhibition  values  of  RIC  against  an  EC90 
concentration  of  RBV.  The  two  lead  compounds,  RIC-2  (EC50=0.3  uM)  and  RIC-1 
(EC50=0.11 uM), were further used as representative compounds for the series in order to 
better understand their mechanism of action. Both compounds had the conserved central 
ring structure seen throughout the RIC series with structural alterations made only to side 
compounds. Due to the conserved structure and their high activity these compounds were 
decided to be representative of the series in future testing. 15 
 
  
 
 
Figure 1: Ability of Lead compounds to return Influenza growth after treatment with 45 uM RBV. Panel A Six of 
the top compounds identified from primary HTS screening (uM) were diluted against 45 uM (EC90) RBV to quantify 
their reversal of RBV's antiviral activity in H1N1. Viral growth was determined based on the degree of neuraminidase 
activity after a 72 hr incubation.  B: Cytotoxicity of RIC-1 on MDCK cells was determined in the absence of viral 
infection and used cellular ATP levels measured with Cell Titer-Glo as a determination of cell viability. C. Inhibition of 
RBV’s antiviral activity by RIC-1. D. Inhibition of RBV by RIC-2. All data points represent the average of 4 replicates 
each compared to the cell only controls (0 uM RIC-1). 
 
The intent of the high throughput screen was to use RBV as a viral mutagen thereby 
artificially  pushing  the  RDRP  past  the  error  threshold  with  the  intent  of  identifying 
compounds that could return viral growth via an increase in RDRP fidelity. However, due 
to the uncertainty concerning the antiviral mechanism of RBV in influenza, four main 
possibilities were subsequently tested to better understand the mechanism by which the 
RIC series inhibits RBV (Figure 2). 16 
 
 
 
Figure 2 Possible sites of interaction between the RIC compound series and RBV. Four possible sites of interaction 
were investigated for possible involvement in the anti-Ribavirin activity demonstrated by the RIC series. The intended 
function of RDRP fidelity (upper left), alleviation of IMPDH inhibition by RBV thereby returning a normal distribution 
of nucleotide pools (upper right), inhibition of ENT-1 preventing cellular uptake of RBV (lower right), or by a direct 
chemical inactivation of RBV by the RIC series (lower left).  
 
RBV specificity testing using multiple nucleoside analogs 
To assess whether the alleviation of viral inhibition was caused through an increase in the 
fidelity  of  the  viral  RDRP  or  if  the  compound  series  was  acting  in  a  RBV  specific 
manner, independent of any polymerase involvement, RIC-2 was tested against various 
other nucleoside analogs. Nucleoside analogs have shown the most promise in decreasing 
the RDRP fidelity and pushing viral populations past the error threshold [21].  17 
 
 
Figure 3. Inhibitory effect of Ribavirin and 5-Fluorouracil on Influenza. Of the six tested, two nucleotide analogs, 
RBV and 5FU, demonstrated an ability to inhibit viral growth (A and B). Ribavirin showed greater efficacy with an 
EC50 around 10 uM compared to an EC50 of 20 uM for 5FU. No cytotoxicity was seen for RBV at the concentrations 
tested (C) while 5FU showed minor cytotoxicity associated with a 20% drop in cellular ATP levels at 100uM (D). Cell 
viability was determined using Cell-Titer Glo to measure the amount of ATP/well which was then compared to the 
average ATP/well from the cell only controls. Values for EC’s and CC’s represent the average of four replicates 
 
The efficacy of RIC-2 against multiple analogs would suggest a mechanism of action that 
was not specific to RBV. Excluding a RBV specific mechanism of viral population rescue 
would support the RIC series acting to increase RDRP fidelity thereby saving the virus 
from an error catastrophe.  
Multiple nucleoside analogs were tested including Azacytidine (AZT), 6-Mercaptopurine 
(6MP), Fludarabine phosphate (FAF) and Thioguanine (TG); only the analog 5- 18 
 
 
Figure 4. Comparison of RIC-2's ability to relieve viral inhibition resulting from treatment with either RBV (A) 
or 5FU (B). Three RIC-compounds, RIC-2 (Green), RIC-6 (Blue) and RIC-5 (Red) were tested for their ability to 
reverse the effect of multiple nucleoside analogs in a concentration dependent manner. Values represent the average 
from  4  replicates  at  each  concentration.  Percent  viral  growth  is  calculated  as  relative  neuraminidase  activity  in 
comparison to the average of 10 virus only control wells. 
 
Fluoruracil (5FU) successfully inhibited influenza growth with an EC50 value of 20 uM 
(Figure 3B). No cytotoxicity was seen at this concentration but testing up to 100 uM 5FU 
resulted in a moderate 18% decline in cellular viability (Figure 3D). Azacitidine showed 
complete cytotoxicity at 6 uM, while concentrations up to 250 uM of 6MP, FAF and TG 
demonstrated no effect on influenza growth after 72 hours. 
Three of the first compounds identified in the RIC series, RIC-2, RIC-5, and RIC-6, were 
tested against an EC90 concentration of RBV and then an EC90 concentration of 5FU to 
measure their ability to relieve viral inhibition by both mutagens. All three compounds 
demonstrated a dose dependent increase in viral growth against RBV treated cells with 
compounds RIC-2 and  RIC-6 able to completely  rescue viral growth (Figure 4A).  In 
contrast, this result was not seen when the three RIC compounds were diluted against 
5FU (Figure 4B). The viral growth remained constant at 5-15% and did not demonstrate a 19 
 
dose dependent response at any concentration of RIC compound. Viral growth inhibited 
by 5FU was not influenced by any of these three compounds. These data suggest the 
compound  series  alleviates  RBV  viral  inhibition  in  a  manner  separate  from  viral 
inhibition caused by 5FU.  
Emergent Mutation Assay 
In an environment without a selecting pressure, mutations occur randomly at a constant 
rate. The large population size of diverse variants all randomly mutating would result in 
little phenotypic alteration in the viral population [7].  The addition of Zanamivir acts as a 
selective pressure to preserve variants with acquired resistance to Zanamivir. Since the 
virus’s ability to gain resistance is dependent on the low fidelity of its RDRP, compounds 
that  increase  the  fidelity  will  slow  or  prevent  the  development  and  enrichment  of 
emergent variants that are resistant to Zanamivir. The rate at which a viral population of 
influenza acquired resistance to the antiviral Zanamivir was measured in the presence and 
absence of RIC-2.  
If RIC-2 increased polymerase fidelity we would expect to see a decrease in the rate of 
acquired resistance, resulting in continued growth inhibition throughout all passages.  
Since each well was passaged separate from the others each passage had 384 unique viral 
populations. The amount of viral growth in each well was measured for all 4 passages 
and compared to the virus only control DMSO plate. In this way the variation in the viral 
growth in each well was measured over four passages. Viral growth per well was sorted 
into 20% ranges of growth and separated based on passage number. The distribution of 
viral growth based on treatment type is shown as a histogram in Figure 6.   20 
 
 
 
 
 
 
 
 
Figure  5.  Cyclic  serial  passage  treatment  plan  for  selection  of  Zanamivir  resistance  in  Influenza.  Using  a 
uniformly treated 384 well culture plate for each group (MDCK cells), four treatment groups consisting of a DMSO 
control, Zanamivir only (EC50), RIC-2 only (1.92 uM), and RIC-2+Zanamivir were serially passaged twice a week. 
Passage 1 plates were directly infected with stock Influenza at an MOI of 0.05. Each consecutive passage was infected 
with a dilution of the supernatant from the preceding passage. Neuraminidase activity per well was measured in the 
preceding plate, after viral transfer, as a measure of viral growth. In this way, 384 viral populations/treatment were 
grown for 17 days. 
 
The neuraminidase activity per well is compared to the average amount of neuraminidase 
activity per well from the DMSO passage plates which were set as “100% viral growth” 
for all plates in that particular passage.   
The DMSO only control plate showed a consistent Gaussian distribution over all four 
passages centered around 100% viral growth. Treatment with “RIC-2 only” demonstrated 
a similar distribution as the DMSO control group for all passages (data not shown). Since 
RIC-2 does not act on viral growth alone but rather prevents an inhibition of growth due 
to treatment with RBV, treating virus with RIC-2 alone was not expected to affect viral 
growth rates. A small portion of the DMSO only group (14 wells) ended with less than 
20% growth in passage four. These wells were randomly distributed throughout the plate 21 
 
and are interpreted to be lost due to procedural techniques. Transfer of virus from plate to 
plate using a small sample of the supernatant induces some inconsistency in the exact 
number of PFU’s transferred. Fourteen wells after 4 passages are therefore considered the 
likeliness  that  any  well  might  be  lost  due  to  the  experimental  design  rather  than  by 
treatment with Zanamivir in the other two plates. 
Passages 1 and 2 of the “Zan-only” treated plate showed slightly rightward weighted 
Gaussian distributions (Figure 6). Passage 1 had a mean value of 51.4 percent while 
passage two had a mean of 55.1 percent viral growth. Passage 1 of the cotreated plate 
showed  a  leftward  weighted  Gaussian  with  a  mean  value  of  55.5  percent.  Passage  2 
showed a more standard Gaussian distribution with a mean of 41.1 percent viral growth. 
The Gaussian distributions of viral growth are indicative of populations that exist with 
naturally occurring genomic heterogeneity. Due to its large size, the initial stock viral 
population  will  inherently  consist  of  some  variants  with  a  modified  sensitivity  to 
Zanamivir. An EC50 value of Zanamivir therefore represents the concentration at which 
the population as a whole resulted in 50 percent viral growth. The distribution around the 
50 percent value initially depends on the range of Zanamivir susceptibility of each variant 
present.  As  seen  in  the  first  passage  of  Figure  6  a  very  small  percent  of  the  wells 
demonstrated  100%  viral  growth  indicating  a  number  of  variants  in  the  original 
population  conveyed  a  complete  resistance  to  the  EC50  concentration  of  Zanamivir. 
These variants were immediately able to replicate at a normal rate. 
A redistribution of growth is seen in passages 3 and 4 with Zan-only and the cotreated 
viral populations moving to broadly occupying all  22 
 
 
Figure 6. Histogram showing effect of RIC-2 on the  distribution of viral growth after serial passage in the 
presence of Zanamivir. The neuraminidase activity in each well was compared to the average value of the DMSO only 
plate resulting in the percent viral growth for that well. Using the calculated viral growth per well, 384 populations per 
treatment were separated into bins representing a 20% range in viral growth. The total number of wells in each 20% 
interval is shown. 
 
percentiles in a bimodal distribution by passage 4. 
Passage  3  of  the  cotreated  plate  had  substantial  representation  across  all  percentiles 
(<20% to 100-120%) with a 22 well range between the most and least populated states. A 
single peak of 104 wells at <20% viral growth was present with a gradual rightward 
decline into the higher growth range. The overall trend seen in the transition from plate 2 
to  3  is  a  shift  of  viral  populations  into  areas  of  increased  viral  growth  seen  by  the 
redistribution  into  more  heavily  populated  percentages.    This  redistribution  of  viral 
populations into the bins of higher growth is seen to continue into passage 4 resulting in a 
bimodal distribution. Both the “zan-only” and the cotreated plate demonstrate an increase 
in the number of populations over 80% viral growth. A major viral growth peak at is seen 23 
 
in  both  treatment  groups  centered  around  80%-100%  with  over  two-thirds  of  each 
population  over  50%  viral  growth.  A  small  subset  of  each  population  demonstrated 
significant inhibition of viral growth resulting in a minor peak seen <20% growth. Viral 
populations  from  both  zan  treated  samples  demonstrated  a  highly  similar  distribution 
despite treatment with RIC-2 suggesting RIC-2 does not influence viral growth in the 
presence of Zanamivir. 
After four passages no variation was seen in the distribution of viral populations between 
the Zanamivir only and the group treated additionally with RIC-2. Both groups rapidly 
and equally experienced a shift in the viral population from a single normal distribution 
centered around 50% growth to a bimodal distribution with peaks centered around 20% 
and 80%. Passage 4 of the Zan-only group had 84 wells under 20% viral growth and 166 
wells over 80-100% viral growth. Similarly the co-treated plate finished with 53 wells 
under 20% and 156 wells over 80% growth. 
As expected, treatment with the antiviral Zanamivir initially resulted in an inhibition of 
viral growth which was eventually overcome after 17 days of viral growth. Treatment 
with RIC-2 did not appear to alter the rate of acquired resistance as both the zan only and 
cotreated  plate  demonstrate  identical  shifts.  Furthermore,  the  number  of  populations 
demonstrating an increase in viral growth is also identical despite treatment with RIC-2. 
Both plates treated with Zan ended with equal portions of the total population growing to 
over 80% viral growth 
Preincubation of RBV with RIC-1 to measure for a direct chemical inactivation of RBV 
A chemical interaction, occurring independent of cellular activity, between RBV and  24 
 
 
Figure 7: Effect of Preincubation on the RIC-1/RBV interaction. A dilution of RIC-1 was preincubated in MDCK-
ULTRA media at 37°C for either 6 hours (circles), 3 hours (triangles) or 0 hours (squares) before being added to 
MDCK  cells  infected  with  Influenza  (A).  Neuraminidase  activity  was  measured  after  a  72  hour  incubation  and 
compared to virus only control providing a percent viral growth in each well. Furthermore, both compounds were 
preincubated separately for 6 hours and then tested against each other and against the opposite compound that had not 
been preincubated (B). Points are an average of 3 replicates. 
 
RIC-2  could  result  in  an  alteration  of  the  chemical  structure  of  RBV,  causing  an 
inhibition of RBV’s mechanism of action either by preventing cellular uptake, altering 
binding to its target site, an increased instability, or by decreasing solubility leading to 
precipitation. 
A concentrated range of RIC-1 concentrations were incubated with 17x RBV in “neat” 
serum free MDCK-ULTRA media for 6 hours and 3 hours. At t=0 aliquots of the media 
containing the preincubated compound combinations were transferred to a tissue culture 
plate in order to treat them with the correct concentration of preincubated RBV and RIC-
1.  This  tissue  culture  plate  was  then  infected  with  influenza.  Viral  growth  in  these 
samples was compared to viral growth in cells treated with RIC-1 and RBV that had not 
been  preincubated.  If  RIC-1  were  directly  chemically  interacting  with  RBV  prior  to 
cellular entry it could render RBV inactive and explain the reversal in antiviral activity. If 25 
 
this were true, then preincubation of the two compounds should result in a decrease in the 
effectiveness of RBV, with longer preincubation times resulting in greater viral growth. A 
six hour preincubation did not result in greater viral growth and in fact maintained a 
complete inhibition of virus (Figure 7a). Three hours of incubation resulted in only the 
highest RIC-1 concentration showing a modest 18% reversal of RBV activity, compared 
to the 92% reversal of RIC-1 added at T=0. The complete inhibition of viral growth at six 
and three hours indicates full functionality of RBV when incubated with RIC-1 for these 
durations.  
When the two compounds were immediately added to cell culture without preincubation, 
RIC-1 demonstrated a typical dose dependent reversal of RBV. In comparison, the six 
hour  preincubation  showed  complete  viral  inhibition  by  RBV  suggesting  a  loss  of 
functionality of RIC-1.  
Furthermore, RIC-1 incubated alone in neat media for 6 hours and then tested against 
RBV, which had not been preincubated, again showed inhibition of viral growth (Figure 
7b). The antiviral effect of Ribavirin, preincubated alone for six hours in media, was 
reversed with the addition of RIC-1, which had not been preincubated; indicating fresh 
RIC-1 was capable of interacting with preincubated RBV, while preincubated RIC-1 is 
not (Figure 7b). Taken together, these data indicate a decrease in the activity of RIC-1 
with increasing preincubation times, possibly resulting from instability of RIC-1 at 37°C. 
No loss of function in RBV was seen due to preincubation with RIC-1 indicating the 
interaction between RIC-1 and RBV does not occur through an extracellular chemical 
inactivation of Ribavirin.  
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Figure 8. Effect of short incubation times on efficacy of RIC-1 and RIC-2 in inhibiting 45 uM RBV: Triplicate 
five point dilutions of either RIC-1 (A) or RIC-2 (B) were incubated with cells for decreasing amounts of time (60 
minutes=solid  line  w/  closed  circles,  15  minutes=dotted  line  w/open  circles,  2.5  minutes=dashed  line  w/  closed 
triangles, and Control added after wash=dashed/dotted line w/open triangles). Cells were then rinsed thoroughly with 
cold DPBS to remove any unreacted compound and new growth media was added. Activity against 45 uM RBV was 
measured based on the ability to return viral growth to control values after 72hr incubation. Viral growth was based on 
measured neuraminidase activity. 
 
 
Rate of Association between RIC-1 and its Target Site 
The antiviral nature of RBV is dependent on multiple generations of virus. As a result, all 
screening measured viral growth 96 hours after the addition of RBV and RIC-1 treatment. 
Paradoxically, RIC-1 showed an apparent instability at 37º C with an almost complete 
loss of function in 3 hours. Somehow RIC-1 was able to inhibit RBV for the entire assay 
long after it should have degraded due to instability. 
To understand the kinetics of RIC-1 activity, the rate of association between RIC-1 and its 
target were measured by decreasing the duration of treatment with RIC-1. Rather than 
leaving the RIC compound in the well for the entire assay, as we had previously done, 
after the desired incubation time, the cell monolayer was rinsed to remove all unreacted 
RIC-1. Cells were then treated with 45 uM RBV and infected in new  growth media 
lacking any additional RIC-1, insuring only RIC-1 utilized during the initial incubation  27 
 
 
 
 
 
was  available  to  act  antagonistically  to  the  continuously  present  RBV.  In  order  to 
establish a positive control for RBV inhibition a portion of the plate was treated with a 
dilution of RIC-1 without washing.  RIC-1 at 0.5 uM or higher demonstrated the ability 
to completely inhibit RBV at all incubation time points down to 2.5 minutes (Figure 8a). 
A time dependent loss of functionality was seen at decreased concentrations. This loss 
was seen with decreasing incubation times experiencing a larger decline in RIC function 
at  concentrations  below  0.5  uM  RIC-1  (Figure  8a).  Treatment  with  RIC-2  showed  a 
partial loss of functionality even at the highest concentration tested, with only 3.0uM for 
a 60 minutes incubation resulting in complete RBV inhibition. Decreasing the duration of 
incubation resulted in linear loss in activity at the higher concentrations but an increasing 
decline in function at the lowest concentrations of RIC-2. 
These data suggest that the loss of function of the RIC series when incubated in media at 
37°C is avoided due to a rapid interaction with the cell. Incubating the cells with 1 uM 
RIC-1 for 2.5 minutes resulted in a complete inhibition of RBV for the full 72 hour assay 
indicating a rapid utilization of the compound and resulting in a prolonged anti-ribavirin 
effect. These results may be explained by either a quick association with the target of 
action resulting in a long lasting alteration of function or through a rapid uptake and a 
prolonged intracellular stability. RIC-2 demonstrated a less efficient utilization by the 
cell. Due to the structural similarity  and approximate size between RIC-1 and RIC-2 
these data suggest a dramatic alteration in the rate of interaction due to small chemical 
modifications.  28 
 
Cellular Uptake of RBV 
While Ribavirin’s MOA is unclear, inhibition of RBV uptake by the cellular Equilibrative 
Nucleoside Transporter 1 (ENT-1) results in a form of resistance to the antiviral effects of 
RBV [41,42]. Cellular uptake of RBV is mediated solely  by ENT-1  and ENT-2 with 
transport via ENT-1 accounting for the majority of the uptake [41]. Inhibition of ENT-1 
by the RIC series would block the cellular uptake of RBV and subsequently prevent the 
viral growth inhibition caused by RBV. 
To assess whether treatment with RIC-1 could alter cellular uptake of RBV we measured 
the amount of RBV in cell samples pretreated with RIC-1, the ENT-1 inhibitor NBMPR, 
or with neat media (control) prior to a 20 minute incubation with RBV. The cell 
monolayer was then collected in acetonitrile and the concentration of RBV in the cell 
suspension was determined using Mass Spectroscopy to quantitatively measure the 
amount of internalized RBV. 
Multiple concentrations of RBV were used in order to establish a correlation between the 
measured  RBV  levels  and  the  concentration  used  in  treatment.  The  measured  RBV 
concentration in the 1x, 5x and 10x “RBV only” samples returned values of 1774 ng/ml, 
6765  ng/ml  and  10,770  ng/ml  respectively  (Figure  9),  verifying  that  measured  RBV 
concentration varies with the treatment concentration. 
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Figure 9. Cellular uptake of RBV (inferred to be mainly by ENT-1) in the presence of RIC-1. MDCK cells were 
incubated with RIC-1, NBMPR, or a media control for 1 hour before a 20 minute incubation with 150 uM RBV. After a 
4 second rinse with ice cold DPBS the cell pellet was collected in acetonitrile and the RBV concentration was measured 
using mass spectrometry. Data points represent the average value of 3 replicates with two wells from a homogenously 
treated 6 well plate combined for each replicate. The 750 uM and 1500 uM RBV samples represent one replicate 
consisting of two combined wells. The long wash consisted of two separate 30 second rinses with cold DPBS. 
 
One of the samples treated with 150 uM RBV received a long wash in cold DPBS with 
the intent of allowing time for the equilibration of RBV out of the cell to demonstrate free 
movement both in and out of the cell. This sample resulted in 83.4 ng/ml approximately 
one and a third logs below the short wash samples. 
Contrary  to  expectations,  the  sample  treated  with  the  ENT-1  and  ENT-2  inhibitor, 
NBMPR, resulted in 1955 ng/ml representing a slight increase compared to the RBV only 
sample. Treatment with 50 uM NBMPR is shown to completely inhibit RBV uptake by 
ENT-1 and ENT-2 resulting in no intracellular uptake of RBV and therefore should act as 
positive control for the experiment. An equal concentration of RBV in both the positive 
and negative controls seriously calls into question the validity of the data. For this reason 30 
 
it  cannot  be  conclusively  stated  whether  the  measured  RBV  was  intracellular, 
extracellular or membrane bound. However, a second experiment using a viral growth 
readout (data not shown) to measure NBMPR’s effect on RBV also showed the NBMPR 
stock has a complete lack of activity against RBV. Despite treatment with NBMPR there 
was a continued complete depression of viral growth due to the RBV activity. These 
results  combined  could  suggest  an  inactivity  of  the  NBMPR  stock  rather  than 
necessitating an invalidation of the results obtained from the uptake experiment. 
The sample pretreated with RIC-1 had a RBV concentration of 1826 ng/ml in the cell 
pellet representing a 52 ng/ml increase compared to the RBV only sample. While the 
failure  of  the  positive  control  makes  a  conclusion  from  this  data  difficult,  an 
approximately equal amount of RBV was measured despite treatment with RIC-1. Since 
RIC-1 actively inhibits RBV in a viral readout it can safely be concluded that RIC-1 was 
active in the uptake assay as well. If the mechanism of action were through inhibition of 
the  ENT-1  transporter  we  would  expect  to  see  a  dramatic  decrease  in  the  measured 
amount of RBV. 
RIC involvement with the IMPDH Pathway 
One possible mechanism of action attributed to RBV is through inhibition of the IMPDH 
enzymatic pathway preventing de novo synthesis of guanine nucleosides. The resulting 
imbalance of nucleotide pools in the cell would lead to an increase in the number of 
incorrectly incorporated bases and an eventual error catastrophe. In order to determine a 
possible interaction between RIC and IMP  
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Figure 10. Effect of RIC on IMPDH inhibition by Mycophenolic Acid (MPA). Viral growth was inhibited by 
treatment with multiple concentrations of MPA and then treated with a 7 point dilution of RIC-1 (0.0 uM to 15 uM). 
Data points represent an average of 4 replicates. Neuraminidase activity per well was compared to average activity 
from 8 virus-only control wells to establish the percent viral growth. The MPA concentrations used were; 102 uM 
(diamond w/dashed-dotted line), 52 uM (squares w/dashed line), 13 uM (triangles w/dotted line), 1.8 uM (Circles 
w/solid line).  
 
dehydrogenase  we  tested  the  ability  of  RIC-1  to  alleviate  inhibition  of  the  IMPDH 
enzyme due to treatment with the IMPDH inhibitor mycophenolic acid (MPA).   
As expected, treatment with higher levels of MPA resulted in a greater depression of viral 
replication  with  102  uM  MPA  resulting  in  almost  complete  inhibition.  Increasing 
amounts of RIC-1 did not produce a dose dependent increase in neuraminidase activity. 
Viral growth remained uniformly inhibited by MPA at all concentrations of RIC-1 used 
with a similar increase in growth of approximately 4% seen at 15 uM across all dilutions 
of MPA. Since the viral growth increase occurred equally across all MPA concentrations 
it is concluded to be a result of cytotoxicity of the 15 uM RIC-1. As seen in Figure 1b, 15 
uM RIC-1 results in an 80% loss in cell viability. This increased cellular stress likely 
resulted in the surviving cells becoming more vulnerable to viral infection. 32 
 
Discussion 
While  many  compounds  are  available  for  the  treatment  of  bacterial  infections  and 
pathogenesis, few exist that are capable of long term management of riboviruses. The 
characteristically low fidelity of the RDRP used by riboviruses coupled with their large 
population size creates a swarm of genotypically unique variants requiring an antiviral 
compound to be effective not only against all present variants but also against any future 
mutations [43,44]. The overall fitness of a riboviral population is therefore closely tied to 
the fidelity of its RDRP. Limiting the mutation rate of the RDRP is highly detrimental to 
the  virus’s  overall  replicative  fitness  and  results  in  a  genotypically  homogenous 
population. Compounds which increase the polymerase fidelity therefore may represent a 
viable therapeutic option for the treatment of RNA viruses when used concurrently with 
current  antivirals.  By  limiting  the  rate  of  mutation,  viral  species  would  be  unable  to 
mutate in response to both medically prescribed compounds and the immune response 
making them more susceptible to treatment. 
Our goal was to identify compounds capable of increasing the fidelity of the Influenza A 
H1N1  RDRP  using  high  throughput  screening  against  a  viral  infection  artificially 
depressed by the mutagen Ribavirin. High throughput screening revealed a compound 
series  capable  of  reversing  the  antiviral  effects  of  RBV  at  sub  micro-molar 
concentrations. The intent of this screen was to identify compounds that increased the 
fidelity of the RDRP thereby limiting the mutation and adaptation rate of RNA viruses 
which  would  have  the  end  result  of  creating  a  genetically  homogenous  and  stable 
population with lowered fitness and a greater susceptibility to antiviral treatment. The 33 
 
nucleoside analog RBV is shown to act antagonistically to viral growth and has been 
suggested to do so through an increased mutation rate causing an error catastrophe in the 
replication of the viral genome. A compound which increased the fidelity of the RDRP 
would be more resistant to the mutagenic effects of RBV by decreasing the chance of 
incorporating an incorrect nucleotide or nucleotide analog.  
The HTS screen identified the RIC compound series as being capable of inhibiting the 
antiviral effects of RBV in cell culture. In order to screen out hits with RBV specificity, 
initial follow-up screening focused on using other mutagenic nucleoside analogs in order 
to establish efficacy of the RIC series against multiple analogs. Activity of the series 
against multiple analogs would suggest a broad spectrum MOA, while inactivity against 
all but RBV would strongly suggest a RBV specific activity. Further testing indicated the 
RIC-series  was  not  effective  against  a  second  nucleoside  analog  5-Fluorouracil.  The 
identification of only one other analog inhibitory to viral growth drastically decreased the 
conclusiveness of this test. While inactivity of the RIC-2 series against 5FU may support 
a possible RBV specific MOA, an equally valid explanation is a selective increase in 
fidelity. That is, the series does function as a fidelity modifier but is not effective against 
5FU. Ribavirin's structure is analogous to a purine while 5FU is similar to pyrimidines. 
The RIC-2 series may only functionally enhance RDRP fidelity in regards to the insertion 
of purines into the elongating chain while not affecting the selectivity for pyrimidines. 
Without  testing  against  other  “purine-like”  mutagens  or  even  a  greater  number  of 
analogs, the series’ inability to inhibit 5FU is inconclusive. 
In order to move toward a more natural setting for which the drug was intended, the rate 34 
 
of  developed  resistance  to  the  antiviral  Zanamivir  was  measured  in  viral  populations 
treated with RIC-2. The initial Gaussian distributions centered on 50% viral growth are a 
testament  to  the  heterogeneity  of  the  original  viral  stock  (Figure  6).  Each  randomly 
created variant carries with it a unique sensitivity to the Zanamivir treatment resulting in 
a  normal  distribution  in  growth.  The  bimodal  distribution  after  17  days  indicates 
approximately a quarter of the wells in both “zan-only” and “zan+RIC-2” were incapable 
of viral  growth.  In these wells none of the variants initially present and none of the 
subsequent mutations were able to survive in the presence of Zanamivir. A small portion 
of the DMSO control also demonstrated less than 20 percent viral growth. The majority 
of these wells showed a complete lack of neuraminidase activity and are assumed to be 
“lost” wells due to procedural techniques used in the serial infection. 
A dramatic increase in the number of wells with over 80% viral growth is seen after only 
17 days of growth. Due to the large number of wells it is concluded that the demonstrated 
resistance derives from emergent mutations in newly formed variants over the course of 
the experiment rather than by enrichment of preexisting resistant variants. The H1N1 
genome is approximately 13,820 nucleotides long [51]. As there are 3 possible mutations 
at each site expression of every point mutation would take 41,000 different variants and 
expression  of  all  mutants  with  unique  sets  of  2  mutations  would  take  hundreds  of 
thousands of unique variants. Realistically there could exist millions of unique clones in a 
given  viral  population,  only  some  of  which  offering  Zanamivir  resistance.  The  low 
frequency of functional mutants with increased Zanamivir resistance makes it unlikely 
that 50 wells each initially received at least one resistant variant. As seen in the original 35 
 
passage some wells initially showed 100% viral growth indicating they did in fact receive 
variants conferring complete resistance. However, the 1-2 wells per plate are within the 
expected frequency. Furthermore these wells show that if a resistant variant were initially 
present in each of these 100+ wells we should have seen complete viral growth in the first 
passage in each well. Instead, a gradual shift in the distribution of populations is seen 
moving from passage 2 to passage 4. Even after 7 days of growth very few wells in both 
the treatment groups have complete viral growth suggesting there are a limited number of 
wells containing variants capable of complete resistance.  
The rate of acquired resistance was quicker than expected, however, and may indicate 
this experiment simply gave these variants a competitive advantage by inhibiting non 
resistant  mutants.  Assuming  resistance  virions  were  present  in  all  wells  initially, 
treatment  with  Zanamivir  would  hinder  the  growth  of  other  variants  allowing  rapid 
growth of resistant genomes. However, in order to accept this explanation there would 
have had to be a prevalence of at least 1 variant demonstrating complete resistance in 
every 250 plated virions. Due to the genetic diversity demonstrated by RNA viruses we 
find  this  frequency  to  be  a  much  more  improbable  explanation.    For  this  reason  the 
increase in wells over 80% growth is concluded to represent the development of emergent 
mutant  variants  not  originally  present  in  the  initial  viral  stock.  Deep  sequencing 
approaches  could  be  used  in  the  future  to  verify  this  conclusion  by  comparing  the 
genotypes from passage 1 and passage 4 and looking for any similarities or conserved 
sequences. 
Throughout  the  experiment  both  “zan-only”  and  “zan+RIC-2”  had  nearly  identical 36 
 
population  distributions.  By  passage  4  both  treatments  demonstrated  significant 
resistance to Zanamivir in over half the populations. As it is concluded that the resistance 
demonstrated  in  passage  4  represents  the  emergence  of  new  variants  then  these  data 
suggest RIC-2 had no effect on the rate of acquired resistance. Since mutation rate is 
dependent on the fidelity of the viral RDRP, the equal rate of resistance suggests both 
treatment  groups  operated  at  equal  fidelities.  Coupled  with  the  inability  of  RIC-2  to 
alleviate  inhibition  of  5FU  these  data  strongly  suggest  a  mechanism  of  action 
independent of RDRP fidelity modification. 
The compounds, RIC-1 and RIC-2, were initially  selected to be representative of the 
entire RIC series. This series is defined by a conserved core structure partially appearing 
similar  to  a  purine-like  fused  ring. All  compounds  in  the  series  demonstrating  some 
degree of efficacy against RBV contain this conserved structure causing us to conclude it 
is necessary for the anti-RBV  effect. RIC-1  and RIC-2 showed the most pronounced 
efficacy  against  RBV  making  them  ideal  for  MOA  studies.  Due  to  their  conserved 
structure with the RIC series we feel justified in generalizing conclusions determined 
using  these  two  compounds  to  the  entire  RIC-series.  Therefore,  based  on  the  results 
obtained we conclude the entire RIC series likely does not function via modification of 
polymerase fidelity.  
While the RIC series does not appear to modify polymerase fidelity it still offered both a 
unique opportunity to study the effect of RBV on viral growth and also a possible insight 
into RBV’s inhibition of viral replication. For this reason, the mechanism of action of the 
RIC  series  was  further  pursued.  First,  however,  we  wished  to  rule  out  a  direct 37 
 
extracellular chemical interaction between RIC and RBV resulting in a modification of 
RBV. Preincubation of RBV with RIC-1 in neat media for 6 hours prior to their addition 
to cell culture did not affect RBV’s antiviral activity (Figure 7).  
Furthermore, in order to get the correct concentration in the cell culture plate the two 
compounds were preincubated at over 17 times their normal concentrations to make up 
for dilution. Despite favorable conditions for a chemical interaction, elevated compound 
concentration and a temperature of 37°C, RBV remained fully functional indicating no 
chemical alteration occurred to RBV. It may be possible, however, that the interaction 
between RIC-1 and RBV is occurring much faster than can be measured with these large 
time scales. In order to measure for a rapid chemical reaction, metabolite analysis using 
mass spectroscopy would be required to monitor any changes in the structure of RBV due 
to incubation with RIC compounds. 
RIC-1  however  did  experience  a  loss  in  efficacy  due  to  preincubation.  The  loss  of 
function  occurs  independent  of  RBV  as  RIC-1  incubated  alone  for  6  hours  was 
completely  ineffective  against  both  preincubated  and  “fresh”  RBV  (Figure  7b).  This 
instability is most interesting as the RBV treatment period for this and all previous assays 
occurs over 72 hours suggesting RIC-1 is able to inhibit RBV 66 hours after it should 
have lost all functionality. The prolonged activity of RIC in cell culture might stem from 
either  an  increased  stability  due  to  interaction  with  the  cell  resulting  for  instance  in 
aggregation or by a rapid mechanism of action resulting in a long lasting alteration to a 
necessary cellular factor for the MOA of RBV. 
In order to better understand how the RIC series inhibited RBV in a prolonged assay, we 38 
 
looked  at  the  kinetics  of  association  between  RIC-1  and  RIC-2  with  their  target  of 
interaction by incubating the RIC compound with MDCK cells for short periods of time 
and then thoroughly rinsing away any excess unbound compound. The rinse consisted of 
four separate volumes of 200 uL cold DPBS with five aspirations and redispensing steps 
with each volume in order to insure complete removal of any unassociated or weakly 
bound RIC compound. The thoroughness of the wash was intended to remove any RIC 
not taken up by the cell. New media treated with 45 uM RBV was added and cells were 
infected. In this way only the RIC utilized in the short incubation was available to inhibit 
RBV left in the media for the entire 72 hour infection.  
The results from Figure 8 indicate that an incubation of RIC-1 with cells for only 2.5 
minutes completely inhibited RBV for the entire assay. Compared to the control dilution 
in Figure 8a, decreasing the incubation time resulted in a more dramatic decrease in viral 
growth at the lower concentrations (<0.8 uM RIC-1). In contrast no time dependent effect 
is seen on the higher concentrations of RIC suggesting a saturation effect. The presence 
of a saturation point would suggest a rate limiting step either in the uptake of RIC-1 or 
the  utilization  of  RIC-1  possibly  resulting  from  a  limit  on  the  amount  of  possible 
intracellular RIC-1, the RIC-1 amount where all cellular target proteins are bound, or it 
may represent the concentration where a sufficient amount of RIC is stored in the cell for 
later use. The maximum concentration at which RIC-1 can be fully utilized by the cell is 
0.8  uM  RIC  for  2.5  minutes.  Decreasing  the  incubation  time  or  RIC-1  concentration 
below this saturation point seems to result in an insufficient amount of RIC-1 acquired by 
the cell. Interestingly, RIC-2 appears to have a higher saturation point of 3.0 uM RIC-2 39 
 
for 60 minutes, suggesting a mechanism not purely based on diffusion to the cell. If the 
rate limiting step were based solely on the rate of diffusion of RIC into the cell then the 
two compounds should have an equal minimum concentration/time. Our assumption is 
that the structural similarity between the two compounds results in their use of the same 
transport protein into the cell. These data indicate that a common protein between the two 
compounds binds RIC-1 more efficiently than RIC-2. Two possible explanations could be 
RIC-1 is more efficiently transported into the cell, or RIC-1 has a greater affinity for its 
target site and is able to bind with a greater frequency than RIC-2. 
Figure  11  further  shows  that  an  increase  in  the  concentration  of  RBV  is  able  to 
competitively  overcome  RIC  compound  inhibition  with  RIC-2  being  overwhelmed  at 
lower concentrations of RBV than RIC-1. These data indicate RIC-1 and RIC-2 may 
competitively inhibit a protein which otherwise would directly interact with RBV or an 
intermediate target necessary for RBV activity. The ability to reverse RIC-1 inhibition is 
suggestive  of  a  long  term  interaction  with  its  target  protein  rather  than  a  permanent 
alteration  leading  to  degradation  or  inactivity.  If  the  RIC  series  reversed  RBV  via  a 
transient protein binding event leading to a chemical alteration of that protein then we 
would not expect to see a competitive reversal. Figure 11 is better explained by RIC 
binding  to  a  shared  protein  with  higher  affinity  which  could  then  be  subsequently 
reversed due to increased RBV concentrations. Taken together these data might indicate 
RIC quickly binds to a necessary protein in RBV’s mechanism of viral inhibition with a 
stronger  affinity  thereby  preventing  binding  of  RBV.  Furthermore,  this  binding  could 
result in the stabilization of RIC compound enabling a continuous long term inhibition of  40 
 
 
 
Figure 11: Efficacy of RIC-1 and RIC-2 against increasing RBV concentrations. Panel A. A dilution of RIC-1 
(5.64 uM=solid line w/ filled circles, 0.447 uM=dotted line w/open circles, 0.126 uM=dashed line w/filled triangles, 
0.010 uM= dashed/dotted line w/ open triangles, and 0.0 uM RIC-1 control= dashed/dotted with filled squares) was 
incubated with different concentrations of RBV. B. The concentrations of RIC-2 used were; 3.942 uM=dotted line 
w/open circles, 1.323 uM=dashed line w/filled triangles, 0.444 uM= dashed/dotted line w/ open triangles, 0.05 uM= 
long dashed w/ filled squares, and 0.0 uM RIC-2 control= dashed/dotted with open squares. All data points represent a 
single replicate. Viral growth was based on neuraminidase activity and compared to virus only controls. 
 
 
RBV binding.  
While  binding  of  RIC  prevents  RBV  binding  it  does  so  in  a  manner  without  further 
affecting viral growth. That is, treatment with increasing levels of RIC-1 and RIC-2 did 
not result in an increase in growth above control levels and only negatively affected viral 
growth due to cellular cytotoxicity (Figure 11). We further verified this by treating a viral 
infection with only RIC-1 and RIC-2 in the absence of RBV. No dose dependent variation 
was  seen  due  to  treatment  (data  not  shown).  Furthermore,  each  viral  growth  assay 
contained a RIC only dilution control to insure no variation in growth resulted from the 
compound alone. RIC may interact via an allosteric site or through a unique interaction 
separate from the RBV/protein interaction. 
We began further investigation with the first protein RBV comes in contact with, the 
equilibrative nucleoside transporter. All RBV uptake into the cell is mediated by the ENT-
1 and ENT-2 nucleoside transporters. A possible interaction between ENT-1 and the RIC 41 
 
series was investigated by measuring the amount of intracellular RBV in the presence of 
RIC. While the exact mechanism of RBV viral inhibition is unclear there is a general 
consensus  that  RBV  must  first  be  transported  into  the  cell  prior  to  functionality. 
Inhibition  of  ENT-1  and  subsequent  RBV  uptake  would  thereby  prevent  its  viral 
inhibition. Furthermore if RIC bound to ENT-1 in such a way to block RBV transport, 
increasing RBV concentration theoretically could competitively alleviate the blockage 
explaining  the  competiveness  seen  in  Figure  11.  Unfortunately,  due  to  the  positive 
control’s (NBMPR) inability to alter RBV levels, ENT-1 involvement is still unclear. 
However, it is our belief that the failure of NBMPR to decrease measured RBV stems 
from a failure of the compound itself rather than the experimental setup. In order to judge 
the efficacy of NBMPR in inhibiting RBV we cotreated a plate with dilutions of NBMPR 
(0.01 uM up to 10 uM) at different RBV concentrations (0.01 uM up to 5 mM). Viral 
growth  remained  inhibited  at  all  combinations  of  the  dilutions.  NBMPR  did  not 
demonstrate a dose dependent or even minor increase in viral growth even at nanomolar 
concentrations  of  RBV.  Previous  RBV  uptake  studies  show  an  effective  inhibition  of 
RBV uptake by ENT-1 at 10 uM NBMPR against 5 uM RBV [41,42,44,45]. Complete 
inactivity in both the viral readout and uptake assays would suggest an inactive stock 
solution of NBMPR. Furthermore, the mass spectrometry readout of the 1x, 5x and 10x 
samples maintained a dose dependent final concentration of RBV with little variation 
between replicates suggesting an accurate measure of the RBV per well. 
However, with the failure of the positive control we can only speculate as to the location 
of the RBV being measured, whether it is intracellular, extracellular (bound to the plate or 42 
 
residual) RBV left by the wash, or if the RBV was bound to the cellular membrane. The 
tight  standard  deviations  between  replicates  could  suggest  against  residual  RBV  left 
behind by the wash, as we would expect a greater variation between replicates if this 
were the case. The low standard deviation for all samples must stem from a consistent 
retention  of  RBV.  Unfortunately  a  longer  more  thorough  wash  with  the  intent  of 
removing any trace RBV and excluding the residual RBV hypothesis would result in an 
equilibration of RBV out of the cell (Figure 9). Since a longer wash could result in less 
extra and less intracellular RBV this technique does not help to clarify the origin of the 
measured RBV. Concerning membrane bound RBV, the procedures used for treatment of 
cells, rinsing, and collection of the monolayer were similar to those used by other groups 
[41,42,45]. No mention of trans-membrane RBV binding was reported as a source of 
error by these groups.  
The possibility of failure of the positive control due to a breakdown of the NMBPR 
compound  allows  room  for  further  speculation  concerning  interpretation  of  Figure  9. 
While these results are at this point purely speculative equal concentrations of RBV were 
seen in the RBV only plate and the one pretreated with RIC-1. Since we have shown 
RIC-1 to be functional in returning viral growth to control levels with a viral readout, 
with ENT-1 inhibition we would expect to produce a variation in the RBV concentration. 
As a variation does not exist despite a functional RIC-1 compound these results may be 
suggestive of an MOA independent of ENT-1. Repeating this uptake experiment with a 
new  ENT-1  inhibitor  and  or  a  new  functional  NBMPR  stock  would  conclusively 
determine the validity of these speculations. If however NBMPR was in fact functional 43 
 
these data would indicate a failure of the experiment to accurately measure the internal 
RBV levels as treatment with NBMPR should result in a dramatic increase in internalized 
RBV. This is not shown by the data. 
Finally, the role of the IMPDH pathway in RBV inhibition was investigated by measuring 
the effect of RIC-1 on IMPDH inhibition by Mycophenolic Acid. Ribavirin has been  
shown to act as an inhibitor of IMP dehydrogenase thereby preventing de novo purine 
nucleotide synthesis [47]. Inhibiting the conversion of IMP to XMP causes an imbalance 
in the cellular nucleotide pool which is then responsible for the increased mutation rate 
and decline in viral growth [47,48,49].  We found that decreased viral growth as a result 
of IMPDH inhibition with the inhibitor MPA did not respond to treatment with RIC-1 
(Figure 10a). The identical increase seen at 15uM RIC-1 for all concentrations of MPA 
tested  is  attributed  to  the  cytotoxicity  of  RIC-1  at  that  concentration  (Figure  1b). 
Decreasing the cellular fitness and metabolic rate would leave it more vulnerable to viral 
infection. The reduction in the number of nucleotides used by the host leaves a larger 
available stock for the viral polymerase resulting in an increased burst size explaining the 
sudden increase at this concentration. Alternatively the data could suggest a threshold 
value necessary for activity against MPA. If this were the case however we would expect 
to  see  a  larger  increase  in  viral  growth  at  the  smaller  dilutions  of  MPA.  Since  all 
concentrations are affected in a similar manner the effect is concluded to be dependent on 
the RIC-1 concentration’s cytotoxicity. 
There are two types of IMPDH inhibitor, both of which have been shown to result in 
antineoplastic, antiviral and immunosuppressive activity. Nucleoside inhibitors such as 44 
 
RBV are typically nucleoside analogs while non-nucleoside inhibitors mimic co-factors 
of  IMPDH  such  as  NAD  [49].  MPA  acts  as  a  non-nucleoside  IMPDH  inhibitor  and 
therefore acts in a unique pathway separate from RBV. For this reason RIC-1’s inactivity 
against MPA cannot be correlated directly to RBV. We have shown that if RIC-1 were a 
competitive inhibitor of RBV binding to IMP dehydrogenase it does so without affecting 
non-nucleoside  inhibition.  Future  research  would  investigate  a  possible  interaction  of 
RIC-1 in preventing the inhibition of the IMPDH pathway with the nucleoside inhibitor 
tiazofurin. This would more accurately correlate to a RBV specific MOA.  
While  the  intended  function  of  the  RIC  series  was  eliminated,  this  compound  series 
demonstrates  competitive  inhibition  of  a  necessary  protein  in  RBV’s  MOA.  Further 
research  into  ENT-1  and  IMPDH  inhibition  may  further  clarify  a  currently  unclear 
antiviral mechanism resulting from treatment with RBV. If RIC-1 is shown to alleviate 
inhibition of IMPDH by a different nucleoside inhibitor this data would be among the 
first to identify RBV’s antiviral mechanism of action as being dependent on inhibition of 
the IMPDH pathway in influenza. 45 
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